The new report, which was published by Urban Institute researchers with funding from the Robert Wood Johnson Foundation, examines historical trends for flu vaccination that indicate ways to address racial, ethnic, and economic inequities in the rollout of coronavirus vaccines. The report is based on data from the 2016 to 2018 National Health Interview Survey.

The proposed standard would likely require employers to create a company-specific plan to minimize worker exposure to COVID-19. The rule is expected to mandate mask-wearing, social distancing, hand-washing breaks, and communication procedures for workers during outbreaks. The new standard, which many feel is long overdue, is expected to protect the most at-risk workers.

Those performing such “aerosol-generating” procedures, often in an intensive care unit, got the best protective gear even if there wasn’t enough to go around, per Centers for Disease Control and Prevention guidelines. And for anyone else working with COVID patients, until a month ago, a surgical mask was considered sufficient. A new wave of research now shows that several of those procedures were not the most hazardous. Recent studies have determined that a basic cough produces about 20 times more particles than intubation, a procedure one doctor likened to the risk of being next to a nuclear reactor.

In a recent study of COVID-19 patients hospitalized with severe acute respiratory infection, functional impairment was found in 53.8% of patients four months after hospital discharge. Long COVID symptoms include cough, shortness of breath, anxiety and depression, cardiac issues, fatigue, deconditioning, and hair loss.

The incidents range from 335 discarded doses in Lee County, North Carolina, that were damaged in shipping, to nearly 5,000 doses that went to waste in Tennessee in February, prompting additional federal oversight. 

On November 9, bamlanivimab became the first monoclonal antibody to receive an emergency use authorization (EUA) for the treatment of COVID-19 patients. The EUA for bamlanivimab marked a milestone in the coronavirus pandemic because the monoclonal antibody became the first medication that could be administered to COVID-19 patients on an outpatient basis.

Vaccination is widely viewed as an end-game stage in the coronavirus pandemic. One of the primary goals of vaccination is to achieve herd immunity—a point at which enough of the country’s population will have immunity to the coronavirus that community spread is unlikely.

Since June 2020, the ICU Survivor Center at Indiana University Health Methodist Hospital in Indianapolis has treated about 100 COVID-19 patients who survived ICU-level care. The patients are experiencing a range of symptoms, according to Sikandar Khan, DO, medical director at the ICU Survivor Center and a research scientist at the Regenstrief Institute in Indianapolis.

On episode 23 of PSQH: The Podcast, Dr. Kent Locklear, chief medical officer of Lightbeam Health Solutions, talks about the ins and outs of COVID-19 vaccine distribution.